MINT-ACYCLOVIR TABLET
国: カナダ
言語: 英語
ソース: Health Canada
製品の特徴
(SPC)
21-01-2022
この製品の一部のドキュメントは現在利用できません。カスタマーサービスにリクエストを送信できます。入手可能になり次第、お知らせします。
リクエストを送信します。
リクエストを送信します。
有効成分:
ACYCLOVIR
から入手可能:
MINT PHARMACEUTICALS INC
ATCコード:
J05AB01
INN（国際名）:
ACYCLOVIR
投薬量:
200MG
医薬品形態:
TABLET
構図:
ACYCLOVIR 200MG
投与経路:
ORAL
パッケージ内のユニット:
15G/50G
処方タイプ:
Prescription
製品概要:
Active ingredient group (AIG) number: 0115506002; AHFS:
認証ステータス:
APPROVED
承認日:
2022-01-25
製品の特徴
PRODUCT MONOGRAPH
PR
MINT-ACYCLOVIR
ACYCLOVIR TABLETS USP
200 MG, 400 MG AND 800 MG
ANTIVIRAL AGENT
MINT PHARMACEUTICALS INC.
DATE OF PREPARATION:
6575 DAVAND DRIVE
JANUARY 21, 2022
MISSISSAUGA, ONTARIO
L5T 2M3
Control No. 239932
_MINT-ACYCLOVIR Product Monograph_
_ _
_Page 2 of 37 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.................................................. 3 SUMMARY PRODUCT
INFORMATION........................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................
3
CONTRAINDICATIONS
.................................................................................................
4
WARNINGS AND
PRECAUTIONS.................................................................................
4
ADVERSE REACTIONS
.................................................................................................
6
DRUG INTERACTIONS
..................................................................................................
9
DOSAGE AND ADMINISTRATION
...............................................................................
9
OVERDOSAGE
..............................................................................................................11
ACTION AND CLINICAL PHARMACOLOGY
.............................................................12
STORAGE AND STABILITY
.........................................................................................14
DOSAGE FORMS, COMPOSITION AND PACKAGING
...............................................14
PART II: SCIENTIFIC
INFORMATION.......................................................................
15
PHARMACEUTICAL INFORMATION
..........................................................................15
CLINICAL TRIALS
........................................................................................................15
DETAILED PHARMACOLOGY
....................................................................................16
VIR
完全なドキュメントを読む
